Turning the Tide: Early PCSK9 Intervention Post-ACS - Episode 10

Safety Data on PCSK9i Inclisiran

Published on: May 8, 2025

Nihar R. Desai, MD, MPH, Martha Gulati, MD MS FACC FAHA FASPC FESC, Alan S. Brown, MD MHA FACC FAHA MNLA, Kirk U. Knowlton MD

Panelists discuss how the VICTORION-INCEPTION study demonstrates the favorable safety profile of inclisiran, showing it is well tolerated with minimal adverse effects, making it a valuable option for patients with high-risk post-acute coronary syndrome needing additional lowering of low-density lipoprotein cholesterol (LDL-C) levels.

EP. 1: The Cumulative Burden of Lipoprotein Cholesterol (LDL-C)

EP. 2: The Risk of a Recurrent Event After ACS

EP. 3: Current Decision Pathway and Guidelines on LDL Management Post-ACS

EP. 4: Can LDL-C Be Too Low?

EP. 5: Challenges to Reaching LDL-C Goal

EP. 6: Benefits of PCSK9i Demonstrated in Intracoronary Imaging

EP. 7: PCSK9 Inhibitors

EP. 8: VICTORION-INCEPTION Study

EP. 9: Top Line Results of VICTORION-INCEPTION

Now Viewing

EP. 10: Safety Data on PCSK9i Inclisiran